تحميل

تدبير بناء الثقة "زاي"

مرافق إنتاج اللقاحات

The BioReliance® Services business of Merck KGaA is primarily a Contract Testing Organisation, providing biosafety testing services for a wide range of global, biopharmaceutical companies.

The Glasgow facility also has a biomanufacturing facility. No products are manufactured for direct sale - only contract manufacturing for others. Typical products produced are (i) Cell Banks, (ii) Virus Seed Stocks and (iii) Viral Vectors.

Anthrax vaccine manufacture

Influenza: Manufacture of influenza vaccine based on WHO recommendations

Japanese Encephalitis Viral Vaccine

Valneva manufactures Japanese Encephalitis Viral vaccine (IXIARO®/JESPECT®) at its cGMP facilities in Livingston, Scotland. The site is licensed and operates under a Manufacturing Authorisation granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

During 2021 Influenza vaccines and the adjuvant MF59 were manufactured at this facility: four distinct products for the market, Agrippal®, Fluad®, Fluad QIV®, (seasonal influenza strain presentations, the latter two formulated with MF59 adjuvant) and Aflunov (pre-pandemic strain presentation).

Covid-19 Vaccine manufacture

Cobra Biologics, Keele is an MHRA licensed facility for the contract development and manufacture of Investigational Medicinal products; these being cell banks (microbial and mammalian), plasmid DNA and viral vector products for gene therapy uses.  Currently the site has a restricted commercial licence granted by the MHRA for the manufacture of COVID-19 vaccine AZD1222 bulk drug substance.

Coronavirus disease (COVID-19)

[Licensed for bulk drug substance manufacturing and testing via MHRA manufacturer’s authorisations MIA 18480 and MIA (IMP) 18480].